CN113817796A - Application of melanoma cells in determination of drug-melanin binding capacity - Google Patents
Application of melanoma cells in determination of drug-melanin binding capacity Download PDFInfo
- Publication number
- CN113817796A CN113817796A CN202011410672.1A CN202011410672A CN113817796A CN 113817796 A CN113817796 A CN 113817796A CN 202011410672 A CN202011410672 A CN 202011410672A CN 113817796 A CN113817796 A CN 113817796A
- Authority
- CN
- China
- Prior art keywords
- melanin
- drug
- determination
- melanoma cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 45
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000003556 assay Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 18
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 23
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 16
- 239000012224 working solution Substances 0.000 description 15
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000011550 stock solution Substances 0.000 description 11
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 9
- 238000003908 quality control method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- WQVZLXWQESQGIF-UHFFFAOYSA-N Labetalol hydrochloride Chemical compound Cl.C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 WQVZLXWQESQGIF-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960003091 labetalol hydrochloride Drugs 0.000 description 4
- 230000036564 melanin content Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229960004171 hydroxychloroquine Drugs 0.000 description 3
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 231100000327 ocular toxicity Toxicity 0.000 description 3
- 239000013062 quality control Sample Substances 0.000 description 3
- 230000004382 visual function Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 206010061137 Ocular toxicity Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108010066676 Abrin Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000007684 eye toxicity Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of melanoma cells in determination of drug-melanin binding capacity. The melanoma cell is mouse melanoma cell B16-F10. The invention verifies that the melanoma cells of the mice are used for determining the binding capacity of the medicament-melanin, and the accuracy and the stability of the determination result are superior to those of the prior primary RPE cell determination method and the free melanin determination method; and the tolerance of mouse melanoma cells (such as B16F 10) to drugs is higher than that of primary RPE cells, and the mouse melanoma cells can tolerate stronger drug side effects in the determination of drug-melanin binding capacity, namely the mouse melanoma cells are suitable for determination scenes with higher drug concentration.
Description
Technical Field
The invention belongs to the field of drug detection, and particularly relates to application of melanoma cells in determination of drug-melanin binding capacity.
Background
Melanin is an anionic polymer and is found widely in the eye, skin, brain and inner ear. Melanin is distributed in the eye in the uveal layer (including iris, ciliary body and choroid) and the Retinal Pigment Epithelium (RPE). Many drugs bind to melanin, accumulate in ocular tissues, affect their pharmacokinetics in the eye, interfere with normal retinal function, and have unpredictable effects on vision. Not only ophthalmic drugs, but also many non-ophthalmic drugs administered systemically are combined with ocular melanin, for example, hydroxychloroquine, which is the most widely used drug for treating systemic lupus erythematosus, and the most clinically significant adverse reaction is ocular toxicity such as macular degeneration and retinal atrophy. It has been found that chloroquine and hydroxychloroquine have affinity for pigmented tissues, particularly with the RPE in the eye, and thus, ocular toxicity resulting from administration of hydroxychloroquine may be associated with melanin binding; the antipsychotic thioridazine also has an affinity for pigmented tissues, accumulates in the RPE and causes destruction of retinal pigment at high doses. Fundus examination of patients taking thioridazine for a prolonged period of time revealed that the RPE of the patient formed a pigmented large plaque with a loss of choroidal capillaries, which could ultimately lead to progressive macular degeneration and loss of visual function if rigorous visual function monitoring was not performed during dosing. In addition, chlorpromazine, tamoxifen, memantine and other drugs all show high eye melanin binding capacity, although not all drugs with high affinity with melanin will certainly cause eye toxicity, the phenomenon of drug-melanin binding should be paid attention to. On the one hand, drug-melanin binding can affect the pharmacokinetics and pharmacodynamics of the drug itself; on the other hand, RPE plays an important role in maintaining the integrity and physiological functions of retinal photoreceptor cells, and toxic effects on RPE will eventually affect the optic nerve, resulting in loss of visual function.
Currently, there are two main methods for in vitro study of the binding ability of melanin, namely: one is in vitro incubation of free melanin with drugs, the melanin is artificially synthesized or extracted from animal eyes; the other type is in vitro incubation of drugs and melanin-containing cells, a common cell model is primary RPE cells of pigs or cows, the freshly extracted primary RPE cells are rich in melanin, but the extraction process is complex and is easily polluted by other types of cells in tissues, the primary RPE cells have no melanin synthesis capacity, and the content of melanin in the cells is continuously reduced along with the increase of the number of passages.
Disclosure of Invention
The invention aims to solve the technical problems that in the prior art, the difference between the drug-melanin binding numerical value and in-vivo metabolism of the free melanin determination is large, and the melanin content in primary RPE cells is reduced along with the increase of the passage number, and provides the application of melanoma cells in the drug-melanin binding capacity determination.
The inventor of the invention who uses melanoma cells does not perform experiments in the field, so that the feasibility of the mouse melanoma cell B16 in determination of drug-melanin binding capacity is verified, and the effects of simplifying experimental procedures and stabilizing test results can be achieved by unexpectedly finding that melanoma cells, particularly B16-F10, have excellent effects.
In order to solve the above technical problems, one of the technical solutions provided by the present invention is: use of a melanoma cell in an assay for drug-melanin binding ability, wherein the melanoma cell is mouse melanoma cell B16.
The mouse melanoma cell B16 can be conventional in the art, and is preferably a mouse melanoma cell B16-F10.
Preferably, the assay comprises the steps of: and mixing the melanoma cells with the medicament and then culturing. The culture time is preferably 15-25 h; more preferably, the time of the cultivation is 20 hours.
The density of the melanoma cells during the culturing process is preferably 1 × 1052X 10 per mL5one/mL, more preferably 1.25X 105one/mL.
In order to solve the above technical problems, the second technical solution provided by the present invention is: a method for detecting a drug-melanin binding ability, wherein the method comprises the steps of:
(1) mixing mouse melanoma cell B16 with the medicine and culturing;
(2) detecting the binding of said drug to said melanin in said mouse melanoma cells.
The preferable definition in the above steps is one of the technical solutions as described above, specifically as follows.
Preferably, the culturing time in the step (1) is 15-25h, preferably 20 h;
wherein the mouse melanoma cell is B16, preferably B16-F10; for example, B16-F10 available from Shanghai Rich Biotech, Inc.
Preferably, the density of the melanoma cells is 1X 10 when the culturing is performed in step (1)52X 10 per mL5one/mL, preferably 1.25X 105one/mL.
Preferably, the binding in step (2) is expressed by the concentration of the drug in the culture supernatant after cell culture.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows:
the invention adopts mouse melanoma cells (preferably B16F 10), which are rich in melanin and have rich and easily-obtained sources, and compared with extracted melanin, the invention has complete barrier and transport mechanism, can regulate the absorption and elimination of drugs from the cells, and is more close to the real biological environment in vivo. The invention verifies that the melanoma cells of the mice are used for determining the binding capacity of the medicament-melanin, and the accuracy and the stability of the determination result are superior to those of the prior primary RPE cell determination method and the free melanin determination method; and the tolerance of mouse melanoma cells (such as B16F 10) to drugs is higher than that of primary RPE cells, and the mouse melanoma cells can tolerate stronger drug side effects in the determination of drug-melanin binding capacity, namely the mouse melanoma cells are suitable for determination scenes with higher drug concentration.
Drawings
FIG. 1 is a standard curve of the relationship between absorbance and melanin concentration measured by an ultraviolet spectrophotometer.
FIG. 2 shows the lower limit of LC-MS/MS quantitation: an analyte.
FIG. 3 shows the lower limit of LC-MS/MS quantitation: an internal standard.
FIG. 4 shows the upper limit of LC-MS/MS quantitation: an analyte.
FIG. 5 shows the upper limit of LC-MS/MS quantitation: an internal standard.
FIG. 6 is a standard curve diagram of LC-MS/MS determination peak area and hydroxychloroquine sulfate drug concentration.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
Experimental materials, reagents, instrument information used in the examples:
1. cell line
Mouse B16F 10 cells, cat no: FH0361, Shanghai Rich and well-balanced Biotech Co., Ltd
2. Reagent
Chloroquine bisulfate:
batch number: 190804, Chongqing Kangle pharmaceuticals, Inc., expiration date: 2021.05.05.
synthesizing melanin:
batch number: BCBZ9117, source: Sigma-Aldrich, effective date: 2029.12.18.
1640 medium:
batch number: 2174114, source: gibco, expiration date: 2020.11.30.
fetal bovine serum:
batch number: 1928700, source: gibco, expiration date: 2024.07.31.
trypsin:
batch number: NM01, source: abrin, effective period: 2021.04.05.
3. materials and instruments
6, a pore plate:
the model is as follows: 3516, brand: costar
Uv-vis spectrophotometer:
the brand model is as follows: agilent Carry60 UV-VIs
Example 1B16 cell culture
Mouse melanoma B16 cells were plated in a cell culture medium containing 10% fetal calf serum and streptomycin (100 kU. L)－1) 1640 medium (pH 7.2) at 37 ℃ with 5% CO2And relative saturation humidity, cells in logarithmic growth phase were taken for subsequent experiments.
EXAMPLE 2 preparation of Hydroxychloroquine sulfate
Adding a certain amount of hydroxychloroquine sulfate into PBS (pH7.4) with a specific volume to make the concentration of the hydroxychloroquine sulfate be 1mM, filtering and sterilizing the hydroxychloroquine sulfate by using a 0.22 mu m microporous filter membrane, diluting the mixture to a corresponding concentration by using a 1640 culture medium, and marking the mixture for later use.
Example 3 Standard Curve for melanin content and determination of drug binding ability to free melanin
10mg of synthetic melanin was weighed, 10mL of PBS was added, and sonication was carried out for 15min to obtain a melanin suspension of 1 mg/mL. Diluted with PBS to 100. mu.g/mL, 50. mu.g/mL, 20. mu.g/mL, 10. mu.g/mL, and 2. mu.g/mL. The absorbance at 475nm was measured. And (3) performing linear regression by taking the absorbance value as an abscissa and the concentration as an ordinate to obtain a standard curve of melanin content: 67.402x-0.5928, R20.9998. See fig. 1.
The results of the determination of the binding capacity of the drug hydroxychloroquine sulfate to free melanin are shown in table 1.
TABLE 1 binding Capacity of Hydroxychloroquine sulfate to synthetic melanin
Example 4 determination of drug-melanin binding Capacity
B16 cells were sampled at 1.25X 105Each mL－1Inoculation in 6-well plates2mL per well, 37 ℃ and 5% CO2The culture was carried out overnight. Adding 2mL of hydroxychloroquine sulfate with the concentration of 0.31, 1, 5, 10 and 20 mu M, setting 3 compound holes, incubating in a constant-temperature incubator at 37 ℃ for 20h, collecting supernatant, and placing in a refrigerator at 4 ℃ for testing.
After collecting the supernatant, the cells were washed 2 times with PBS, digested and collected in a centrifuge tube (total 2mL, 20. mu.L of which was diluted by a certain factor for counting), centrifuged at 1000r/min for 5min, the supernatant was discarded, 1mL of 1mol/L NaOH solution containing 10% DMSO was added, resuspended, incubated in a 80 ℃ water bath for 45min, and the absorbance value at 475nm was determined. Bring the absorbance values into the standard curve (y 67.402x-0.5928, R)20.9998), the corresponding melanin content was determined.
In triplicate, the concentration of hydroxychloroquine sulfate in the cell culture medium after 20h incubation was determined using LC-MS/MS.
LC-MS/MS related parameters and experimental methods:
instrument
·AB SCIEX TRIPLE QUADTM4500 LC-MS instrument
Centrifugal machine
Microanalysis balance, to an accuracy of 0.001mg
Vortex mixer
Pure water meter (resistivity is more than or equal to 18.2M omega cm)
Analyst data acquisition software (Version 1.7.0)
Column chromatography: xbridge BEH C18,2.5 μm, 2.1X 50mm, Waters
Pipet (20. mu.L, 100. mu.L, 200. mu.L, 300. mu.L, 1000. mu.L)
Electric pipette
Second, instrument parameters
1. Liquid phase conditions:
sample introduction amount: 5 μ L
A chromatographic column: xbridge BEH C18,2.5 μm, 2.1X 50mm, Waters
Column temperature: 40.0 deg.C
Sample injector temperature: 4 deg.C
Mobile phase A: 0.1% FA in H2O
Mobile phase B: 0.1% FA in ACN
Operating time: 5.0min
Gradient of mobile phase:
needle washing solvent: strong wash (MeOH: ACN: IPA: DMSO ═ 1:1:1:1, v/v/v/v)
Weak wash (MeOH: H)2O＝1:1，v/v)
Needle washing procedure: rinse Type: External only;
Rinse mode:Before and after aspiration,Dip time:1s；
Rinse pump method:Rinse pump,then Port,Time:2s；
Rinse settings:Rinsing speed:35μL/s；
Rinse volume:500μL；
Measuring line purge volume:100μL；
retention time:
2. conditions of Mass Spectrometry
The instrument model is as follows: AB SCIEX TRIPLE QUADTM 4500
An ion source: ESI
Ionization mode: positive ion
MRM ion pair:
the instrument parameters are as follows:
| parameter(s) | Chloroquine bisulfate | Labetalol |
| IS(v) | 5500 | 5500 |
| TEM(℃) | 500 | 500 |
| CAD | 9 | 9 |
| CUR(psi) | 30 | 30 |
| Gas 1(psi) | 25 | 25 |
| Gas 2(psi) | 40 | 40 |
| DP(v) | 115 | 65 |
| EP(v) | 10 | 10 |
| CE(v) | 30 | 20 |
| CXP(v) | 14 | 11 |
Preparation of reagent
1. Mobile phase a (mpa): 0.1% FA in H2O
Take 1000mL of H2And adding 1mL of FA into the O solution in a solvent bottle, and mixing uniformly. The shelf life is 1 month at room temperature.
2. Mobile phase b (mpb): 0.1% FA in ACN
1000mL of ACN was added to 1mL of FA in a solvent bottle and mixed well. The shelf life is 1 month at room temperature.
3. Strong wash Solution (SNW): MeOH ACN IPA DMSO 1:1:1:1, v/v/v 500mL MeOH, 500mL ACN, 500mL IPA, 500mL DMSO was mixed well.
The shelf life is 3 months at room temperature.
4. Weak wash solution (WNW): ACN H2O＝1:1，v/v
1000mL of ACN and 1000mL of H were taken2And O, and mixing uniformly. The shelf life is 3 months at room temperature.
5. Working solution diluent&The solvent (Diluent) is MeOH H2O＝1:1，v/v
500mL of MeOH and 500mL of H were added2And O, and mixing uniformly. The shelf life is 3 months at room temperature.
6. Precipitant (Precipitant) MeOH
500mL of MeOH was taken. Shelf life at room temperature of 3 months
7. Stock dilutions (dilution 1): MeOH
Take 30mL MeOH. The shelf life is 3 months at room temperature.
8. Labetalol stock dilution (dilution 2): DMSO (dimethylsulfoxide)
30mL of DMSO was taken. The shelf life is 3 months at room temperature.
Preparation of standard curve and quality control
The stock solution and the working solution are both stored in an ultra-low temperature refrigerator (70 ℃ below zero to 90 ℃ below zero).
1. Preparation of stock solution of standard yeast
Precisely weighing a proper amount of hydroxychloroquine sulfate in a sample bottle, adding a proper amount of methanol, ultrasonically dissolving, shaking up, and preparing into a standard yeast stock solution with the concentration of 0.500 mg/mL. (the mass conversion factor is 0.773.)
2. Standard song&Preparation of SST working solution (working solution diluent: MeOH: H)2O＝1:1)
Standard koji & SST working liquids were obtained using standard koji stock solutions, formulated according to the following table:
preparation of hydroxychloroquine sulfate standard curve & SST working solution
3. Preparation of Standard Curve & SST samples
Standard curve & SST working solutions were used, formulated according to the following table, to obtain standard curve & SST samples:
preparation of hydroxychloroquine sulfate standard curve & SST sample
The standard curve samples were stored in an ultra-low temperature freezer (-90 to-70 ℃).
4. Preparation of quality control stock solution
Precisely weighing a proper amount of hydroxychloroquine sulfate in a sample bottle, adding a proper amount of methanol, ultrasonically dissolving, shaking uniformly, and preparing into a quality control stock solution with the concentration of 0.500 mg/mL. (the mass conversion factor of hydroxychloroquine sulfate is 0.773.)
5. Preparation of quality control working solution (working solution diluent: MeOH: H)2O(ml:ml)＝1:1)
Using the quality control stock solution, preparing according to the following table to obtain a quality control working solution:
preparation of hydroxychloroquine sulfate quality control working solution
6. Preparation of quality control sample
Using a quality control working solution, preparing according to the following table to obtain a quality control sample:
preparation of hydroxychloroquine sulfate quality control sample
The quality control samples were stored in an ultra-low temperature freezer (-70 to-90 ℃).
7. Preparation of internal standard stock solution
Accurately weighing a proper amount of labetalol hydrochloride into a brown sample bottle, adding a proper amount of labetalol hydrochloride stock solution diluent, dissolving and shaking up to prepare an internal standard stock solution with the concentration of 1.000 mg/mL. (the mass conversion factor of labetalol hydrochloride is 0.998.)
Preparation of internal standard working solution (working solution diluent: MeOH: H)2O＝1:1)
Internal standard working solutions were prepared according to the following table using internal standard stock solutions:
preparation of labetalol hydrochloride internal standard working solution
Fifthly, sample treatment step
The LC-MS/MS results are shown in FIGS. 2-5.
The standard curve of LC-MS/MS determination peak area and hydroxychloroquine sulfate drug concentration is shown in FIG. 6, and the standard curve is that y is 0.00569x-0.000292, R2＝0.9958。
And (3) performing linear least square regression calculation on the theoretical concentration of the analyte in the standard curve by comparing the peak area of the analyte with the peak area of the internal standard, and calculating the actually measured concentration of the analyte in the sample by using the obtained regression equation. The concentration of hydroxychloroquine sulfate initially added is [ L ]0]And the concentration of hydroxychloroquine sulfate in the supernatant measured after 20h incubation was [ L]Calculating the ratio of the hydroxychloroquine sulfate at different initial concentrations to the concentration of hydroxychloroquine sulfate in the culture medium according to the formula (1):
Vwvolume of culture Medium per well, VcellCell volume (3. mu.L/10)6Individual cell), m is the mass of melanin in the cell.
The results of the binding capacity assay of hydroxychloroquine sulfate to mouse B16-F10 cells are shown in Table 2.
TABLE 2 binding Capacity of Hydroxychloroquine sulfate to B16 cells
From the above table, it can be seen that: the use of melanoma cells allows for accurate and stable determination of free melanin.
Claims (10)
1. Use of a melanoma cell in an assay for drug-melanin binding ability, wherein the melanoma cell is mouse melanoma cell B16.
2. The use of claim 1, wherein the melanoma cell is mouse melanoma cell B16-F10.
3. Use according to claim 1 or 2, wherein said determination comprises the steps of: and mixing the melanoma cells with the medicament and then culturing.
4. The use according to claim 3, wherein the incubation time is 15-25 h; preferably, the time of the cultivation is 20 h.
5. The use of claim 4, wherein the melanoma cells have a density of 1 x 1052X 10 per mL5Per mL; preferably, the density of melanoma cells is 1.25 × 105one/mL.
6. A method for detecting a drug-melanin binding ability, wherein the method comprises the steps of:
(1) mixing mouse melanoma cell B16 with the medicine and culturing;
(2) detecting the binding of said drug to said melanin in said mouse melanoma cells.
7. The assay of claim 6, wherein the incubation time in step (1) is 15-25h, preferably 20 h;
and/or the mouse melanoma cell B16 is B16-F10.
8. The detection method according to claim 6, wherein the density of the melanoma cells is 1X 10 when the culture is performed in step (1)52X 10 per mL5one/mL.
9. The assay of claim 8, wherein the melanoma cells are at a density of 1.25 x 105one/mL.
10. The assay of any one of claims 6 to 9 wherein the binding in step (2) is expressed by the concentration of the drug in the culture supernatant after cell culture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011410672.1A CN113817796B (en) | 2020-12-03 | 2020-12-03 | Application of melanoma cells in drug-melanin binding capacity measurement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011410672.1A CN113817796B (en) | 2020-12-03 | 2020-12-03 | Application of melanoma cells in drug-melanin binding capacity measurement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113817796A true CN113817796A (en) | 2021-12-21 |
| CN113817796B CN113817796B (en) | 2023-12-26 |
Family
ID=78924957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011410672.1A Active CN113817796B (en) | 2020-12-03 | 2020-12-03 | Application of melanoma cells in drug-melanin binding capacity measurement |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113817796B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749559A (en) * | 1986-06-02 | 1988-06-07 | United States Of America | Method for detecting melanin-containing matter |
| CN101532950A (en) * | 2008-12-31 | 2009-09-16 | 程树军 | Method for analyzing toxicity and effect of skin whitening agent through human being skin melanocyte |
| CN104297225A (en) * | 2014-09-29 | 2015-01-21 | 无限极（中国）有限公司 | Method for quickly detecting and imaging melanin in cells |
| CN111759962A (en) * | 2020-08-25 | 2020-10-13 | 上海中医药大学附属岳阳中西医结合医院 | Application of Rhizoma Imperata in Melanoma Diseases |
-
2020
- 2020-12-03 CN CN202011410672.1A patent/CN113817796B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749559A (en) * | 1986-06-02 | 1988-06-07 | United States Of America | Method for detecting melanin-containing matter |
| CN101532950A (en) * | 2008-12-31 | 2009-09-16 | 程树军 | Method for analyzing toxicity and effect of skin whitening agent through human being skin melanocyte |
| CN104297225A (en) * | 2014-09-29 | 2015-01-21 | 无限极（中国）有限公司 | Method for quickly detecting and imaging melanin in cells |
| CN111759962A (en) * | 2020-08-25 | 2020-10-13 | 上海中医药大学附属岳阳中西医结合医院 | Application of Rhizoma Imperata in Melanoma Diseases |
Non-Patent Citations (3)
| Title |
|---|
| ANNA-KAISA RIMPELA等: "Drug Distribution to Retinal Pigment Epithelium: Studies on Melanin Binding, Cellular Kinetics, and Single Photon Emission Computed Tomography/Computed Tomography Imaging.", MOL. PHARMACEUTICS * |
| ANNA-KAISA RIMPELA等: "Implications of melanin binding in ocular drug delivery.", ADVANCED DRUG DELIVERY REVIEWS * |
| 王若男;钱仪敏;阮斌;宋硕;李华;: "药物与眼黑色素结合的体内外研究方法及意义", 中国医药工业杂志 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113817796B (en) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casals | Tablet sensitivity testing on pathogenic fungi. | |
| CN112946107B (en) | Analysis method of N-nitrosodimethylamine and N-nitrosodiethylamine in argatroban bulk drug or preparation | |
| EP4424302A1 (en) | Ophthalmic preparation of tyrosine kinase inhibitor, and preparation method therefor and use thereof | |
| CN114002344A (en) | Detection method and kit for olanzapine, aripiprazole and dehydroaripiprazole | |
| Edwards et al. | Endogenous ocular lipids as potential modulators of intraocular pressure | |
| CN108362807B (en) | Hemodialysis liquid detection method and application thereof in pharmacokinetics-pharmacodynamics of pulse-activating injection | |
| CN113817796A (en) | Application of melanoma cells in determination of drug-melanin binding capacity | |
| CN115248263B (en) | An HPLC-MS/MS method for quantitative detection of anti-epileptic drugs in saliva | |
| CN105708844B (en) | A kind of tobramycin dexamethasone nanometer suspension eye drops and preparation method thereof | |
| CN107320710B (en) | Cerebroprotein hydrolysate preparation and design method thereof | |
| CN113135886A (en) | An anti-depression active ketone compound and its screening method | |
| CN107764909B (en) | Determination method of amorolfine hydrochloride and interferent thereof | |
| Yasuhara et al. | Relationship between surface activity and toxicity to Chang liver cultures of tricyclic antidepressants | |
| CN115389640B (en) | A method for determining the content of insulin liposome drug | |
| CN110208442A (en) | A kind of method of the drug concentration of progesterone in detection biological sample | |
| CN109142576A (en) | The detection method of roxithromycin residual quantity in a kind of animal hair | |
| CN102621335A (en) | Blood product and preparation method thereof | |
| CN113933418A (en) | Method for simultaneously detecting concentrations of 7 antibiotic drugs in human serum | |
| CN113567569A (en) | A kind of determination method of Polygonum cuspidatum extract on absorption of quinolones | |
| CN114705640A (en) | High-sensitivity serum zinc determination reagent with strong anti-interference capability and preparation method thereof | |
| CN115919761B (en) | Pazufloxacin mesylate liquid preparation and preparation method thereof | |
| CN116836165B (en) | Curcumin 2-chloroadenine derivative compound | |
| CN114699417B (en) | Application of Sodium Inositol Hexaphosphate in Intestinal Rehabilitation Treatment of Children with Short Bowel Syndrome | |
| CN116270448B (en) | Preparation method of pazufloxacin mesylate liquid preparation | |
| Astorri et al. | Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |